Kazia Therapeutics (KZIA) Equity Average (2009 - 2025)

Kazia Therapeutics has reported Equity Average for 14 years, with the latest figure at $12.6 million in Q4 2025.

• For the quarter ending Q4 2025, Equity Average changed N/A year-over-year to $12.6 million; the trailing twelve-month figure through Dec 2025 stood at $12.6 million (changed N/A YoY), and the FY2025 full-year result was -$6.0 million, down 920.63% from the prior year.
• Equity Average for Q4 2025 stood at $12.6 million, up from -$1.6 million in the prior quarter.
• The five-year high for Equity Average was $26.2 million in Q2 2021, with the low at -$1.6 million in Q2 2024.
• Historically, Equity Average has averaged $12.6 million across 5 years, with a median of $11.5 million in 2022.
• Annual changes were most pronounced in 2021 — Equity Average jumped 196.65% — and 2024, when it tumbled 120.25%.
• Kazia Therapeutics' Equity Average stood at $23.9 million in 2021, then plunged by 56.62% to $10.3 million in 2022, then sank by 44.53% to $5.7 million in 2023, then tumbled by 127.63% to -$1.6 million in 2024, then surged by 894.13% to $12.6 million in 2025.
• The last three Equity Average figures came in at $12.6 million (Q4 2025), -$1.6 million (Q2 2024), and $5.7 million (Q4 2023), per Business Quant data.